Tavaborole (Dermatophytic Onychomycosis)：市場予測と分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 8
2.3 Upcoming Related Reports 9
3 Disease Overview 10
3.1 Etiology and Pathophysiology 10
3.1.1 Etiology 10
3.1.2 Pathophysiology 11
3.1.3 Prognosis 13
3.1.4 Quality of Life 14
3.2 Symptoms 14
4 Disease Management 16
4.1 Treatment Overview 16
4.1.1 Diagnosis 18
4.1.2 Clinical Practice 19
5 Competitive Assessment 24
5.1 Overview 24
5.2 Strategic Competitor Assessment 25
6 Opportunity and Unmet Need 27
6.1 Overview 27
6.2 Unmet Needs 28
6.2.1 Unmet Need: Efficacious Oral and Topical Treatments 28
6.2.2 Unmet Need: Clinical Safety 29
6.2.3 Unmet Need: Patient Awareness 30
6.2.4 Unmet Need: Shorter Treatment Duration 31
6.2.5 Unmet Need: Higher Treatment Rates 31
6.2.6 Unmet Need: Prescribing Guidelines 32
6.2.7 Unmet Need: Differential Diagnosis 32
6.3 Unmet Needs Gap Analysis 33
6.4 Opportunities 34
6.4.1 Opportunity: Decreased Frequency of Dosing 34
6.4.2 Opportunity: Combinatorial Approaches to Treatment 34
7 Clinical Pipeline Assessment 35
7.1 Overview 35
7.2 Promising Drugs in Clinical Development 36
8 Tavaborole 38
8.1 Overview 38
8.2 Efficacy 39
8.3 Safety 40
8.4 Dosing and Formulation 40
8.5 Potential Clinical Positioning 40
8.6 Potential Commercial Positioning 41
8.7 Pricing and Reimbursement 41
8.8 SWOT Analysis 42
8.9 Forecast 42
9 Appendix 43
9.1 Bibliography 43
9.2 Abbreviations 47
9.3 Methodology 48
9.4 Forecasting Methodology 48
9.4.1 Diagnosed DO patients 48
9.4.2 Percent Drug-Treated Patients 49
9.4.3 Drugs Included in Each Therapeutic Class 49
9.4.4 General Pricing Assumptions 49
9.4.5 Pricing of Pipeline Agents 49
9.5 Physicians and Specialists Included in this Study 50
9.6 About the Authors 51
9.6.1 Author 51
9.6.2 Reviewer 51
9.6.3 Global Head of Healthcare 52
9.7 About GlobalData 53
9.8 Disclaimer 53